Boehringer Ingelheim partners with Sino Biopharma on $7 billion cancer drug deal

Boehringer Ingelheim announced a partnership with China's Sino Biopharmaceutical to co-develop cancer therapies.

The agreement targets antibody-drug conjugates and T-cell engager platforms, with a total potential value exceeding $7 billion.

Boehringer will provide an upfront payment of $358 million, with further milestones and royalties linked to development progress.

The collaboration expands Boehringer's footprint in China and highlights the growing trend of Western-Chinese pharma partnerships.